Osokogu Osemeke U, Dodd Caitlin, Pacurariu Alexandra, Kaguelidou Florentia, Weibel Daniel, Sturkenboom Miriam C J M
Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, 3015 CN, The Netherlands.
Dutch Medicines Evaluation Board, Utrecht, The Netherlands.
Drug Saf. 2016 Sep;39(9):873-81. doi: 10.1007/s40264-016-0433-x.
Spontaneous reports of suspected adverse drug reactions (ADRs) can be analyzed to yield additional drug safety evidence for the pediatric population. Signal detection algorithms (SDAs) are required for these analyses; however, the performance of SDAs in the pediatric population specifically is unknown. We tested the performance of two SDAs on pediatric data from the US FDA Adverse Event Reporting System (FAERS) and investigated the impact of age stratification and age adjustment on the performance of SDAs.
We tested the performance of two established SDAs: the proportional reporting ratio (PRR) and the empirical Bayes geometric mean (EBGM) on a pediatric dataset from FAERS (2004-2012). We compared the performance of the SDAs with a published pediatric-specific reference set by calculating diagnostic test-related statistics, including the area under the curve (AUC) of receiver operating characteristics. Impact of age stratification and age-adjustment on the performance of the SDAs was assessed. Age adjustment was performed by pooling (Mantel-Hanszel) stratum-specific estimates.
A total of 115,674 pediatric reports (patients aged 0-18 years) comprising 893,587 drug-event combinations (DECs) were analysed. Crude values of the AUC were similar for both SDAs: 0.731 (PRR) and 0.745 (EBGM). Stratification unmasked four DECs, e.g., 'ibuprofen and thrombocytopenia'. Age adjustment did not improve performance.
The performance of the two tested SDAs was similar in the pediatric population. Age adjustment does not improve performance and is therefore not recommended to be performed routinely. Stratification can reveal new associations, and therefore is recommended when either drug use is age-specific or when an age-specific risk is suspected.
对疑似药品不良反应(ADR)的自发报告进行分析,可为儿科人群提供更多的药物安全性证据。这些分析需要信号检测算法(SDA);然而,SDA在儿科人群中的具体性能尚不清楚。我们在美国食品药品监督管理局不良事件报告系统(FAERS)的儿科数据上测试了两种SDA的性能,并研究了年龄分层和年龄调整对SDA性能的影响。
我们在FAERS(2004 - 2012年)的儿科数据集中测试了两种既定的SDA:比例报告比(PRR)和经验贝叶斯几何均值(EBGM)。我们通过计算与诊断测试相关的统计数据,包括接受者操作特征曲线下面积(AUC),将SDA的性能与已发表的儿科特定参考集进行比较。评估了年龄分层和年龄调整对SDA性能的影响。年龄调整通过合并(Mantel-Hanszel)特定层估计值来进行。
共分析了115,674份儿科报告(0至18岁患者),包含893,587种药物-事件组合(DEC)。两种SDA的AUC粗略值相似:0.731(PRR)和0.745(EBGM)。分层揭示了四种DEC,例如“布洛芬与血小板减少症”。年龄调整并未改善性能。
在儿科人群中,两种测试的SDA性能相似。年龄调整并不能提高性能,因此不建议常规进行。分层可以揭示新的关联,因此当药物使用具有年龄特异性或怀疑存在年龄特异性风险时,建议进行分层。